



## UN high-level meeting on TB: Treatment targets

GLOBAL


**TUBERCULOSIS** 




## UN high-level meeting on TB: TB preventive treatment targets



# New tools and regimens needed to reach 2035 targets in global TB incidence rates





World Health Organization

consolidated

quidelines on

tuberculosis

Module 2: Screening

active

tuberculosis

Principles and

recommendations

World Health Organization


# **Learnings from the National TB Prevalence Survey, 2016:**

Among the bacteriologically confirmed TB:

- 2/3 missed by symptom screen alone
- 98.3% had abnormal chest x-ray findings
- 10% had no risk factors and had no 2weeks cough and/or hemoptysis

Triggered a major shift in screening approaches:

- From passive to active, intensified, enhanced case finding
- More sensitive screening tools (chest x-ray) to triage and identify presumptive TB early
- Use of rapid molecular tests (not sputum microscopy) in active case finding




## **Screening for TB in Targeted Populations**

## **Strong Recommendation:**

- Persons living with HIV (PLHIV) (NNS 10, 74 studies)
- Household/close contacts of TB (NNS 17, 89 studies)
- Prisons and penitentiary institutions
- Works with silica exposure (NNS 36, 18 studies)


### **Conditional recommendation:**

- Among people with risk factor for TB seeking care other than TB symptoms in areas with TB prevalence 100/100,000 in the general population
- Untreated fibrotic CXR lesion
- Subpopulations with structural risk factors for TB (homeless, remote or isolated, indigenous, migrants)



# **Risk Factors for TB for Priority Screening**

- 1. Fibrotic CXR lesion
- 2. Diabetes Mellitus (1.5-2 to 3.1x)
- 3. Previous TB
- 4. Chronic lung diseases (2.5 to 3x)
- 5. Smoking (1.5-2 to 3.3x)
- 6. Alcohol use disorder (1.35-1.9x to 3-3.33x)
- 7. Substance use disorder
- 8. Malnutrition
- 9. Pregnancy
- 10.Immunocompromised organ transplant, renal failure (100x), chronic dialysis (10-25x)
- 11. Healthcare workers (2.94x)



# **Screening Tools for TB**

## **Strong Recommendation:**

 Any of the 4-symptom screen (cough, fever, weight loss, night sweats) <u>+</u> CXR among PLHIV, close contacts

#### **Conditional recommendation:**

- Computer-aided detection software in place of human readers for interpreting CXR and triage for TB (≥15yo)
- C-reactive protein (>5mg/L), CXR or WHO recommended rapid diagnostic tests among PLHIV

# **Step-by-Step Patient Flow/Process**

Walk-through in 10-15 minutes





- ✓ Guides sputum collection while at point of screening
- ✓ Reduces turn around time
- ✓ Improves patient flows

**Chest X-ray with Al** 



**Diagnosis** 

**Sputum Collection On-Site** 





**Referral for Treatment** 











#### Sites:


- Batangas Medical Center, Batangas City, Batangas
- Jose B. Lingad Memorial Regional Hospital, San Fernando City, Pampanga
- Amang Rodriguez Memorial Medical Center, Marikina City, Metro Manila







## Artificial Intelligence (AI) Use in 3 Tertiary Government Hospitals



## **Overall BCTB Yield Rate**

1-2 TB cases/100 screened (1.54%)

Number needed to Screen: 67

## **Overall BC/CDTB Yield Rate**

Total=679 (5.26%)

Number needed to screen: 19

## 49.7% of BCTB cases had no S/Sx

99 cases would have been missed without CXR-AI







## **Implementing Partners:**























## **Program Impact**

ICF using CXR with AI 2019

Community Mass Screening in 3 Big Regions using CXR alone (2018)

**BC-TB Yield Rate** 

1.6% (patients and companions)

1%

**Sputum Submission Rate** 

84.1% (2x higher)

35% to 48%

- Availability of CXR with AI to triage TB improved early lost-tofollow-up rate
- Overall cost analysis showed cost effectiveness
  - Cost loss of USD1,428 (cost of detecting BC case without CXR)
  - Cost loss of USD 1,308 (cost for missed or undetected TB cases)

**USAID's TBIHSS GPPI:** *ICF Among Outpatients and their Companions by A.I.-Read Chest Xray for Tuberculosis Triaging* 

## Cost-Effectiveness Study for CXR-Al in Public Facilities

- Chest x-ray
  - Reduced TB incidence by 1197 and around 55 deaths over 10 years either with AI or human reader
  - Cost of DALY due to TB averted by P43,376 with AI and P47,667 with human readers
  - Requires additional P633 for AI vs P695 for human reader per case
- Use of Al
  - Saved 8.3 hours in waiting and travel per case screened
  - Saved P95 out-of-pocket expense per case screened
  - TB catastrophic cost reduced by at least 0.5% of average HH income
  - Averted productivity losses by P2,200 per screened person diagnosed and P283,203 per screened person treated for TB

## **Recommendations:**

- Assess feasibility of mainstreaming
- Analyze political and operational requirements
- Study acceptability
   among local practitioners
- Consider financing options for LGUs



hosted **UNOPS** 





- Valenzuela City
- Tarlac
- Bataan
- Laguna
- Cebu Province
- South Cotabato









Shift to rapid molecular testing



# Laboratory Strengthening

- 50 GeneXpert Laboratories installed with Laboratory Connectivity (DataToCare)
- Optimized Specimen Referral System (OSRS) in Quezon Province, soon in Cebu and Quezon City
- Partnership with the Philippine Flying Labs to demonstrate use of drone technology for specimen transport in remote sites
- Operations research on the use of stool in the diagnosis of TB in children
- 38 TrueNat Machines in peripheral laboratories and point of care community screening
  - 8 are paired with ultra-portable CXR







# Community Case Finding Activities in Geographically Isolated and Depressed Areas (GIDA)









## Implementation – SOCCSKSARGEN

























# Implementation (Central Visayas)















# Clustered Demo Training Series (Central Visayas & SOCCSKARGEN)



















# Clustered Demo Training Series (NCR & Central Luzon)















# 3

# Private Sector Engagement in Testing



Providing quality diagnostics within your reach

The Philippine Private Sector Diagnostic Consortium

A national platform convening influential players in private diagnostics, negotiates concessional pricing via pooled procurement (high volume – low price strategy), to increase accessibility to quality, affordable TB diagnostics in the private sector

#### **Conditions:**

- Provide uniform pricing to patients
- Provide quality assured diagnostic services
- Notify DOH
- Be monitored



#### For more information:

philcat.ppsdc@gmail.com
https://theconsortium.ph

Improved Access to Rapid molecular testing in the private sector

# Costs reduced *from second highest* in the world *to the third cheapest*

	Current	Consortium	Price Reduction
Test Cost	P8,394	P2,268	73.0%
(to patient)	(average)	(uniform)	/3.0/0

- 23 members to date (15 hospitals, 6 clinics, 1 lab network and 1 HMO) from five (5) regions (NCR, 1, 4A, 4B and 7)
- Procured PHP 27M worth of 18 GeneXpert systems (2-, 4-, 8- and 16-module machines) and 20,800 cartridges as of March 2022
- 12,045 tests done with 23.2% positivity rate, 6.5% had rifampicin resistance
- Savings of PHP 67M if tested in commercial non-consortium members
- Soon to offer testing for HIV viral load, SARS-COV-2, HPV and HBV







Diagnostic Manufacturer and Distributor for GeneXpert Systems



Partner for Pooled Procurement for Other Goods

#### With Technical Support from:







## **TB-COVID-19 Bidirectional Testing**

#### A. Algorithm in quarantine/isolation facilities





















to HCs

#### (1) collected for COVID-19 Xpert MTB/Rif test

Sputum specimen

Specimens sent to SAH RTDL for Xpert MTB/Rif test through specimen transport riders (STRiders)

Results released to field team and MHD through STRiders

#### MHD to facilitate referral of patients

#### B. Algorithm in swabbing facilities





nasopharyngeal swab for COVID-19 RT-PCR









Send specimen to Icasiano HC and Parola HC RTDLs through STRiders









MHD to facilitate referral of patients to HCs





If NO respiratory

symptoms, offer

Chest X-ray through

mobile van

equipped with AI



suggestive of TB,

collect 1 sputum

specimen for Xpert

MTB/Rif testing







Release results to field team and MHD through STRiders





## How Manila is using its COVID-19 response to find TB patients

By Jenny Lei Ravelo // 16 September 2021

Global Health Philippines





residents and non-residents following the implementation of the country's first bidirectional screening and testing for coronavirus disease (COVID-19) and Tuberculosis (TB).

#ReFullvInformed

Dual testing for TB and SARS-CoV-2 in Manila (Philippines)

Consolidated report of country success stories in mitigating the impact of the COVID-19 pandemic on TB services









# 5

# **Electronic TB Medical Advisory Committee (eTBMAC)**



A web-based platform interfaced with a mobile health application that is interoperable with ITIS to provide effective and efficient support on challenging cases of TB from the TB MAC to the medical frontliners using digital technology



## **Regional Coverage**

**LUZON** 

1, 3, 5, CAR, NCR

**VISAYAS** 

6 and 8

**MINDANAO** 

10, 11, 13




## Case Referral, 2022

4	January		
25	February		
47	March		
19	April		
28	May		



## **Type of Referrals**

45	Enrolment	
57	Case Management	
21	Treatment Outcome	











# All Oral Regimens for Drug-Resistant TB

Treatment Outcomes of Patients under Standard All-Oral Regimens, 2019



Treatment Outcomes of Patients under Standard All-Oral Regimens, 2020



- Cured/Completed
- Failed
- Not Evaluated

- Died
- LTFU
- On Treatment



(SSOR)		months/ 5 months: Lfx-Cfz-Z-E	
Regimen 4: Standard Long All Oral Regimen for FQ Susceptible (SLOR FQ-S)	MDR-TB and RR-TB eligible to SLOR (no FQ resistance)	6 Months: Lfx-Bdq-Lzd-Cfz 12-14 months: Lfx-Lzd-Cfz	Request for "off- label" use at TB MAC if extending use of Bdq beyond months.
Regimen 5: Standard Long All Oral Regimen for FQ Resistance (SLOR FQ-R)	MDR-TB and RR-TB eligible to SLOR (with FQ resistance)	6 Months: Lzd-Bdq-Dlm-Cfz-Cs 12-14 months: Lzd-Cfz-Cs	Request for "off- label" use of Bdq and Dlm combination at TB MAC.
Individualized treatment regimen (ITR)	Retreatment MDR-TB and RR-TB cases [not eligible to SSOR nor SLOR]	Construct to have at least 4-5 likely effective drugs	Present the case a TB MAC and follow their advice for the regimen design

(Bdq shall always be given for 6











Cured/Completed

On Treatment

■ Failed



Died

LTFU



7

## **Innovative treatment adherence tools**



Q

RESEARCH BEGINS INTO NEW DIGITAL TOOLS TO SUPPORT PATIENTS AND HEALTHCARE WORKERS THROUGH TUBERCULOSIS TREATMENT

04/08/2021





**Smart Pillbox** 

**Medication Label** 

Video-Observed Treatment (VOT)

# **TB Reporting and Notification Platforms and Apps**



## **ITIS Ph Mobile Development**

Available in both iOs and Android

- Case Management
- Laboratory Module
- Mini Reports
- Daily DOT Diary

- Available in both IOS and Android
- Individualized notification dashboard for the notifying physician
- In-app registration and profile update



# **TB Reporting and Notification Platforms and Apps**





## TB Data Warehouse Design and Development

- Automation of Data Cleaning Report
- KPI Analysis of RaceTB to Go Live
- National TB Program Reports Design
- Ad-hoc Reporting Platform

## Other implementations:

- Deduplication Process
- Standard Facility ID across ITIS Platform
- Automated Notification via FHIR-based Application Program Interface (API)






## **ITIS Alerts**

#### **Email alerts:**

- No treatment Outcome
- Follow Up of Conduct of Diagnostic Test
- Initial Loss to Follow Up

#### SMS:

- Available Laboratory Results (Facility use)
- User Account Validation needed (Regional administrator)



- Patient-centered and responsive
- Evidence-based (health technology assessment)
- Integration-ready in the context of universal health care



Ending TB is everybody's business

#TBFreePH